Thread: Glaxo drug hikes platelets, cuts bleeding in study
View Single Post
  #1 (permalink)  
Old 06-12-2007, 03:55 PM
Jan B. Wade Jan B. Wade is offline
Registered User
  
Join Date: Jan 2003
Posts: 1,438
Thanks: 8
Thanked 121 Times in 71 Posts
Jan B. Wade is on a distinguished road
Glaxo drug hikes platelets, cuts bleeding in study
Glaxo drug hikes platelets, cuts bleeding in study

Sat Jun 9, 2007 8:51am ET

LONDON (Reuters) - GlaxoSmithKline Plc's experimental platelet-boosting drug eltrombopag has produced further positive results in patients with idiopathic thrombocytopenia purpura (ITP), researchers said on Saturday.

Eltrombopag, which Glaxo plans to sell as Revolade in Europe and Promacta in the United States, is one of several novel drugs in the group's pipeline which it believes have blockbuster potential.

Results from a pivotal Phase III study presented at the European Hematology Association congress in Vienna showed 50 to 75 milligrams once daily resulted in a statistically significant increase in platelet counts and also reduced bleeding in people with chronic ITP.

The placebo-controlled trial involved 114 adults and patients studied had previously received and failed current standard ITP treatments.

Read Entire Story
__________________
Mr. Jan B. Wade
Blood Management Consultant
Enhance Outcomes - Control Cost
For Information Call - 360 296-1807
Email

Reply With Quote
The Following 2 Users Say Thank You to Jan B. Wade For This Useful Post:
Bob Jordan (02-08-2008), Informaticus (02-09-2008)